The Belviq Recall

The FDA recently announced the Belviq recall. The reason behind the FDA's action is the increased risk of developing cancer associated with this medication. Eisai Inc. announced the withdrawal of the drug from the U.S., European, and Canadian markets on Feb. 13, 2020. It's important to understand that a withdrawal of a medication is not a recall. It's simply a company's decision to take the medication off the market.

The manufacturer of Belviq, Eisai Inc., knew about the dangers of Belviq and downplayed them in the hope that the drug would be approved by the FDA without long-term testing. However, it is now being recalled because of the serious side effects and the number of cases of women who developed cancer as a result. This company must be held responsible for the harm it caused to patients. Whether or not they were responsible for the FDA's decision to recall the medicine, the company must pay compensation for the illnesses and pain associated with the drug.

The manufacturer of Belviq knowingly concealed the risks of the drug from doctors and patients, causing the product to be widely available. As a result, they were able to keep profiting off the drug even after the FDA ordered it to be recalled. This was a terrible mistake, and it's unfortunate that this product harmed so many women. As a result, those who were diagnosed with cancer may be eligible to take legal action against Eisai Inc.

As a result of this recall, the manufacturers of Belviq will refund any patients who took the medication before the date of the voluntary recall. Additionally, they will also cover any legal fees. If the Belviq recall is not a sufficient remedy, you may pursue legal action in your state or in another country. It's critical that you seek justice for those affected by the drug. If you've already been diagnosed with cancer, you may be eligible for a refund.

In 2010, the FDA raised concerns regarding the cancer risks of Belviq, and the FDA formally rejected it. In rodents, the drug was linked to an increased risk of breast and brain cancer. The manufacturer tried to convince the FDA that these were not likely to occur in humans, but the FDA rejected their request. This led to the voluntary withdrawal of the drug from the market in the U.S. and is now available only through prescription.

According to the FDA, the company knew about the risks associated with Belviq long before it was recalled. In a lawsuit filed against Eisai, the company claims that the FDA should have prevented its wrongful conduct. The lawsuit against Eisai is not only a matter of safety. Instead, it is a matter of financial justice. The lawsuit seeks to compensate victims for any medical expenses, pain, and suffering related to the side effects of the Belviq.